BioNTech to acquire US FDA priority review voucher
SRRK•BioNTech will acquire a US FDA priority review voucher from Scholar Rock for $205 million in cash. The deal is subject to Hart-Scott-Rodino clearance.
1. Voucher deal
BioNTech will acquire a US Food and Drug Administration priority review voucher from Scholar Rock for total cash consideration of $205 million, subject to Hart-Scott-Rodino clearance.
